Advertisement
Canada markets open in 8 hours 44 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.87
    +0.30 (+0.36%)
     

  • Bitcoin CAD

    87,749.94
    -22.89 (-0.03%)
     

  • CMC Crypto 200

    1,389.26
    +6.68 (+0.48%)
     

  • GOLD FUTURES

    2,347.50
    +5.00 (+0.21%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,770.50
    +203.00 (+1.16%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,981.20
    +352.72 (+0.94%)
     

  • CAD/EUR

    0.6828
    +0.0007 (+0.10%)
     

Five Star Equities Issues New Research Reports on GALE, OMER, REGN and ZIOP

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Galena Biopharma Inc. (NASDAQ:GALE - News) shares jumped 9.62 percent to close at $2.28 a share Monday. The stock traded between $2.13 and $2.31 volume of 9.49 million shares traded. The company recently presented a corporate update at the 20th Annual NewsMakers in the Biotech Industry Conference on Friday, September 27th.

Get more information on Galena Biopharma and free access to the in-depth equity report at:
www.FiveStarEquities.com/GALE

Omeros Corporation (NASDAQ:OMER - News) shares declined 1.12 percent to close at $9.75 a share Monday. The stock traded between $9.50 and $10.70 on volume of 2.26 million shares traded. The company announced that the FDA has granted Orphan Drug Designation to Omeros’ OMS824 for the treatment of Huntington's disease. Shares of Omeros have gained approximately 120.0 percent year-to-date.

ADVERTISEMENT

Get more information on Omeros and free access to the in-depth equity report at:
www.FiveStarEquities.com/OMER

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN - News) shares increased 2.36 percent to close at $312.87 a share Monday. The stock traded between $301.97 and $319.83 on volume of 1.14 million shares traded. Piper Jaffray has raised its price target on the company to $360.00 from $336.00. Shares of Regeneron Pharmaceuticals Resources have gained approximately 82.0 percent year-to-date.

Get more information on Regeneron Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/REGN

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP - News) shares spiked 8.84 percent to close at $3.94 a share Monday. The stock traded between $3.62 and $4.19 on volume of 3.35 million shares traded. The company recently presented at the “BioCentury's NewsMakers in the Biotech Industry Conference” on Friday, September 27th.

Get more information on ZIOPHARM Oncology free access to the in-depth equity report at:
www.FiveStarEquities.com/ZIOP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com